HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

RZLT — Rezolute Inc.

RZLT (Rezolute Inc.) stock: $3.68, $355.0M market cap, $90.0M cash, $265.0M EV, $445.1M fully diluted market cap. Lead program: RZ358 (5 mg/kg) (Congenital Hyperinsulinism), Phase 3. Data from Fully Diluted's biotech stocks database.

What they do

Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (“HI”). Summary of Clinical Assets Ersodetug Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.

Source: 10-K FY2026 via SEC EDGAR

Share price
$3.68
Market cap
$355.0M
Cash
$90.0M
Enterprise value
$265.0M

Balance sheet

Cash$90.0M
Debt$0.0M
Net cash$90.0M
Enterprise value$265.0M
Basic shares96.7M shares
Fully diluted shares120.9M shares
Fully diluted market cap$445.1M
Cash per share$0.93
Quarterly burn$13.1M
Cash runway6.8 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.

Share structure

Common
96.7M
Pre-funded warrants
8.2M
Options
12.5M
RSUs
2.2M
Warrants
0.8M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.5M
FDSO
120.9M

Cap table as of 2026-09-21.

Price history

Loading RZLT daily closes…

Loading price history…

Next catalyst

ersodetug · Dec 1-31 · guided in 17d

Recently reported

Ersodetug Phase 3 Positive · 2026-11-13
tumor hyperinsulinism (tumor hi)
Primary: Proportion of patients able to achieve at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency for underlying hypoglycemia — Primary efficacy endpoint has been achieved, based on preliminary results from a November 5th data evaluation; to date, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose
· To achieve statistical significance, the lower bound of the 95% confidence interval for percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants
· Three participants are still in the pivotal period of the study, including two who have not yet met the responder criterion
· One participant discontinued the study early and chose to enter home hospice care, and died one week later due to cancer progression; this participant has been classified as a non-responder
· The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas)
· Ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care
· Topline results for the completed study, including statistical analysis of the primary endpoint, are expected by mid-December 2026
Safety: Ersodetug has been well-tolerated to date in the pivotal and extension phases of the study, with no drug-related safety findings attributed to ersodetug
Source release →
Ersodetug Phase 3 Negative · 2026-10-05
sunRIZE · congenital hyperinsulinism
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 718 stocks.
Subscribe to Compounding Ego